PubMed Health⌕ Search

Biomedical subjects

M A Farias

Publications and source records attributed to M A Farias.

3 recordsLinked to original sources

A prospective comparison of methods for determining if cardiovascular disease is a predictor of mortality in dialysis patients.

A random sample of 464 dialysis patients was surveyed between December 1990 and June 1991 to compare methods for determining the relationship between cardiovascular disease (CVD) and mortality. The following three methods were used to identify the prevalence of CVD: standard epidemiologic questionnaires, recall by the patient, and a review of the medical record. The 1-year mortality rate during this prospective study (average follow-up, 17.5 months) was 19%. The measure of prevalent CVD found to be the best predictor of the risk of mortality was the review of the medical record. Specifically, after controlling for the effects on mortality of age, sex, race, cause of renal failure, serum albumin level, and performance status (determined by the Karnofsky score), a patient with a history of angina pectoris documented in the medical record had a relative risk (95% confidence interval) of mortality of 1.8 (1.1 to 2.8), and a patient with peripheral vascular disease recorded in the medical record had a relative risk of 1.6 (1.0 to 2.4). Estimates of CVD obtained from either the questionnaires or patient recall resulted in associations between CVD and mortality that were substantially weaker than those for the medical record. We conclude that at present the medical record is the best source of information for estimating the presence of CVD as a mortality risk factor in dialysis patients. We recommend inclusion of a medical record history of CVD as a mortality case-mix factor when comparing dialysis populations.

Adult↗

Effect of verapamil on left ventricular function: a randomized, placebo-controlled study.

Verapamil has a negative inotropic action in isolated cardiac muscle. Its effects on left ventricular function were tested in 25 patients with suspected coronary artery disease. A double-blind, randomized, placebo-controlled study design was used. Verapamil (0.2 mg/kg over 10 minutes) significantly lowered mean arterial pressure (from 105 to 89 mm Hg) while increasing the cardiac index (from 2.8 to 3.1 liters/min/m2). No statistically significant effect was seen on heart rate, left ventricular end-diastolic pressure or end-systolic volume index, ejection fraction, peak rates of systolic wall thickening or diastolic wall thinning, or percentage of hemiaxial shortening. However, there was a small increase in the left ventricular end-diastolic volume index (from 94 to 102 ml/m2). Important findings were a reduction in systemic vascular resistance (from 39 to 30 U . m2), an increase in left ventricular end-diastolic volume index consistent with a negative inotropic effect, and no evidence of improved regional wall dynamics in portions of the left ventricular wall considered hypokinetic because of myocardial ischemia.

Cardiac Catheterization↗